Article thumbnail

The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia

By Karin G. E. Miedema, Eveline S. J. M. de Bont, Rob F. M. Oude Elferink, Michel J. van Vliet, Claudi S. M. Oude Nijhuis, Willem A. Kamps and Wim J. E. Tissing
Topics: Original Article
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:3166608
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A et al (2001) Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever.
  2. (1999). Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis 29:414–419
  3. (2009). C-reactive protein levels and radiation-induced mucositis in patients with head-and-neck cancer.
  4. Caviglia I et al (2007) A prospective study on the epidemiology of febrile episodes during chemotherapyinduced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 45:1296–1304
  5. (2009). Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.
  6. (2010). Citrulline-based assessment score: first choice for measuring and monitoring intestinal failure after high-dose chemotherapy. Ann Oncol 21(8):1706–1711 1600 Support Care Cancer
  7. (2000). Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressedonneutrophilsandmonocytes.JImmunol164:4991–4995
  8. Daenen SM et al (2005) Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients.
  9. (2005). Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia.
  10. (2008). Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia.
  11. (2002). guidelines for the use of antimicrobial agents in neutropenic patients with cancer.
  12. (1993). High serum procalcitonin concentrations in patients with sepsis and infection.
  13. (2008). How well do serum sTREM-1 measurements prognosticate in septic shock? Anaesth Intensive Care 36:654–658
  14. (2003). Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol
  15. (2005). Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients.
  16. (1992). Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia.
  17. (1995). Interleukin-8 serum levels for early detection of infectious episodes in neutropenic patients.
  18. (2000). Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation.
  19. Kara A et al (2007) Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia.
  20. (2000). Low-risk” prediction rule for pediatric oncology patients presenting with fever and neutropenia.
  21. MJ et al (2005) Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med
  22. Oude Nijhuis CS, Spijkervet FK et al (2006) The roleoforalmucositisonthesystemicinflammationparameterIL-8in febrile neutropenic cancer patients.
  23. (1999). Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia.
  24. (2001). Prediction of gramnegative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis 32:832–
  25. (2009). Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia.
  26. (2000). Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II.
  27. (1996). Procalcitonin in patients with and without immunosuppression and sepsis.
  28. (1994). Procalcitonin increase after endotoxin injection in normal subjects.
  29. (2009). Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 13:R83
  30. (1966). Quantitative relationshipsbetween circulating leukocytes and infectioninpatients with acute leukemia.
  31. (2009). Risk assessment in fever and neutropenia in children with cancer: What did we learn? Crit Rev Oncol Hematol 72:45–55
  32. (2009). Soluble TREM-1 is not suitable for distinguishing between systemic inflammatory response syndrome and sepsis survivors and nonsurvivors in the early stage of acute inflammation.
  33. (2009). Soluble triggering receptor expressed on myeloid cells-1 is an early marker of infection in the surgical intensive care unit. Surg Infect (Larchmt)
  34. (2005). Surface triggering receptor expressed on myeloid cells 1 expression patterns in septic shock. Intensive Care Med 31:594–597
  35. (2008). Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.
  36. (1992). Value of C-reactive protein determination in the initial diagnostic evaluation of the febrile, neutropenic child with cancer.